|By Business Wire||
|September 6, 2012 06:07 AM EDT||
BioClinica®, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, announced today that Isis Pharmaceuticals will expand its current use of BioClinica’s Express Electronic Data Capture (EDC) solution to several upcoming trials.
Isis is a global leader in antisense drug development with a broad pipeline of drugs that are applicable to many different disease targets. Isis's antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve industry drug discovery productivity.
BioClinica’s Express EDC makes every part of the clinical trial process more efficient and easier to manage. BioClinica Express is a comprehensive EDC solution that uses time-tested, stable technology to provide a central hub to coordinate and organize the collection and dissemination of clean data, adding speed and quality to every part of the clinical trial process.
Isis has used BioClinica’s Express EDC for previous drug studies and, after evaluating competing options, decided to expand its use of Express EDC to a broader range of clinical trials. Isis representatives cite the ease of use, BioClinica’s customer service, and a competitive cost structure as reasons they embraced Express as their EDC of choice.
“Above all else, we are most impressed with the software itself,” said Kevin Nichols, Director of Drug Development Information Systems at Isis Pharmaceuticals. “BioClinica’s Express EDC meets all of our needs, yet is still easy to use. It creates well-organized workflows based on the data that is entered at doctor sites. Beyond its standard features, it is highly customizable and configurable both in the user interface and the way it operates. Unlike other systems, it’s even easy to customize the system after the study starts.”
Mr. Nichols also cited the quality of the service Isis receives from BioClinica, stating that “BioClinica has been always been ready to meet our software enhancement requests. They are open to our suggestions, and use them to make Express better. While Express has great standard features, the BioClinica team understands that customers often have specific needs and does everything they can to meet those needs.”
Cost was an additional factor in the decision to expand Isis’s use of Express EDC. Mr. Nichols explains how “BioClinica offers great value to us as their original base costs are quite comparable to their industry partners, but the overall cost is lower as they do not add the kind of exorbitant fees that other vendors charge for relatively minor adjustments to customize the software or make changes.”
When asked about other EDC providers, Mr. Nichols stated that “We’ve used other leading EDC products in the past, and BioClinica offers equal capability but with better service and value. Compared with the other companies we’ve dealt with, BioClinica seems to be far more interested in customer satisfaction and retention. We would recommend them to any organization who wants a great product backed by outstanding service, at a competitive price.”
“This is our favorite kind of success story,” said Peter Benton, President of BioClinica’s eClinical Solutions. “It is very gratifying when an industry-leading company like Isis Pharmaceuticals is satisfied with our technology and, more importantly, with the service received from BioClinica and decides to expand our relationship. We look forward to continuing to meet and exceed the expectations of our customers every day.”
BioClinica will be demonstrating Express EDC, along with its full line of integrated eClinical solutions and Imaging Core Lab Services, at the Clinical Business Expo September 18 – 20 in Boston, Massachusetts and at the 2012 Society of Clinical Data Management Annual Conference September 22 – 23 in Los Angeles, California.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.